FDA
-
-
-
-
-
-
-
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer
-
-
-
-
-
-
-
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
-
-
-
-
-
-
-
Marker Therapeutics (MRKR) Announces EMA Grants Orphan Drug Designation for MT-401 for Treatment of AML Patients
-
-
-
-
-
-
-
Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™
-
-
-
-
-
-
-
Marker Therapeutics Reports Q2 2022 Operating and Financial Results
-
-
-
-
-
-
-
Marker Therapeutics (MRKR) Issues Clinical and Pipeline Update
-
-
-
-
-
-
-
Pre-Open Stock Movers 03/19: (MRKR) (ZKIN) (CLVS) Higher; (IDRA) (SKLZ) (ROAD) Lower (more...)
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

